A Hong Kong court has granted further leniency to a senior Immigration Department assistant, placing him on a one-year probation order after he was convicted of repeatedly choking his wife and young son during domestic disputes. Kowloon City Court heard on Wednesday that the 49-year-old defendant, identified as “ATK”, preferred probation to community service because he would lose his job and the s...
A Hong Kong court has granted further leniency to a senior Immigration Department assistant, placing him on a one-year probation order after he was convicted of repeatedly choking his wife and young son during domestic disputes. Kowloon City Court heard on Wednesday that the 49-year-old defendant, identified as “ATK”, preferred probation to community service because he would lose his job and the substantial pension accumulated more than 30 years in the disciplined services. He earlier admitted...
Following the death of Ricky Hatton, families and former champions tell a new BBC documentary the sport has not filled the void in care for its fighters.
Following the death of Ricky Hatton, families and former champions tell a new BBC documentary the sport has not filled the void in care for its fighters.
Earnings Call Insights: MaxCyte (MXCT) Q4 2025 Management View Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired SeQure DX, integrated the business, and launched the ExPERT DTx platform. Masoud stated, "We made meaningful changes to rightsize spending and strategically improve our ...
Earnings Call Insights: MaxCyte (MXCT) Q4 2025 Management View Maher Masoud, President, CEO & Executive Director, highlighted that 2025 was a challenging year but also one of "meaningful progress for MaxCyte." The company acquired SeQure DX, integrated the business, and launched the ExPERT DTx platform. Masoud stated, "We made meaningful changes to rightsize spending and strategically improve our operations. And most recently, we launched a new product into ExPERT DTx that will allow us to work with developers earlier in research and filament discovery." Masoud reported $33 million of total revenue for the full year, including $29.6 million of core revenue and $3.4 million of strategic Platform License Program revenue. He noted the installed instrument base grew to 857 units from 760 at the end of 2024. The ExPERT DTx launch targets earlier-stage research and drug discovery, offering a modular 96-well electroporation platform designed to streamline workflows and facilitate progression from discovery to GMP-compliant manufacturing. Masoud outlined 2026 revenue guidance: "we expect total revenue to be in the range of $30 million to $32 million, consisting of $25 million to $27 million of core revenue and $5 million of SPL program-related revenue." He acknowledged a $4 million core revenue headwind from SPL customer program rationalization and a recent license termination, stating, "we expect Q1 to be our lightest quarter for core revenue with the back half weighted year." The CEO emphasized an ongoing commitment to innovation and a belief that "the headwinds facing our business are a result of the conservation of capital by biotechs... which we expect to stabilize in the second half of 2026." On management changes, Masoud announced, "Parmeet Ahuja will be joining MaxCyte as Chief Financial Officer, succeeding Doug Swirsky effective March 30." CFO Douglas Swirsky reported, "Total revenue for the full year was $33 million compared to $38.6 million in 2024, representing ...
Maryviolet/iStock via Getty Images Overview When I previously covered SLR Investment ( SLRC ), I issued a hold rating due to the limited growth potential. Since then, the share price has declined by another 5.5% as the conditions of the debt market continue to deteriorate. SLRC reported its Q4 earnings, and I wanted to revisit the BDC's outlook. SLRC continues to offer some resilience when compare...
Maryviolet/iStock via Getty Images Overview When I previously covered SLR Investment ( SLRC ), I issued a hold rating due to the limited growth potential. Since then, the share price has declined by another 5.5% as the conditions of the debt market continue to deteriorate. SLRC reported its Q4 earnings, and I wanted to revisit the BDC's outlook. SLRC continues to offer some resilience when compared to the rest of the BDC sector, but I do believe there are some downside risks that investors should consider. SLRC has no investments in non-accrual status, but there aren't enough growth catalysts to look forward to. Looking at the performance over the last twelve months, SLRC's share price has declined by more than 15.5%. Even when including all distributions that were paid out to shareholders, the total return still sits at a loss of more than 8% over the same time frame. Due to the decline in share price, SLRC's starting dividend yield now sits around 11.4%. However, net investment income does not support the base distribution level, and management does not have any spillover income available. Therefore, a dividend cut may be needed at some point in 2026. Data by YCharts The share price has fallen into an attractive discount to NAV territory. However, I still don't think this is a good time to accumulate since earnings growth is poor. SLRC has struggled to allocate sufficient capital to new investments that can materialize into higher earnings over time. While interest rates remain high, I believe that the growth potential will continue to be suppressed through 2026. Despite the limited growth, management continues to demonstrate its ability to navigate headwinds. Q4 Earnings Revealed Limited Growth According to the most recent earnings release , SLRC has total investments at a fair value of $3.3B. Approximately 65% of the portfolio is allocated towards floating-rate debt securities, which means that SLRC is capable of collecting elevated interest income from its borr...